All In Biotech

Drug Trial Radar · NCT01009190

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

A Parallel Arms Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: Jun 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Feb 2010

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Lead sponsor
pharmaand GmbHIndustry
Sponsor type
Industry
First posted
Nov 6, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Dose escalation phase 1 study of PARP inhibitor PF-01367338 in combination with chemotherapy in adult patients with advanced solid tumors

Conditions

  • Advanced Solid Tumors

Interventions

  • PF-01367338Drug

    Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle

  • CarboplatinDrug

    Standard doses of intravenous Carboplatin administered every 3 weeks

  • PF-01367338Drug

    RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle

  • CarboplatinDrug

    Standard doses of intravenous Carboplatin administered every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of escalating doses of PF-01367338 in combination with chemotherapy (as defined by first-cycle DLTs)Time frame: 18 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Belfast City Hospital

    Belfast, United Kingdom

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Kings College London

    London, United Kingdom

  • Sir Bobby Robson Cancer Trials Research Centre

    Newcastle upon Tyne, United Kingdom

  • Churchill Hospital

    Oxford, Oxfordshire, United Kingdom

  • Royal Marsden Hospital

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.